Drug Combination Details
| General Information of the Combination (ID: C21946) | |||||
|---|---|---|---|---|---|
| Name | Resveratrol NP Info | + | Trastuzumab Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | HER2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| T-47D | CVCL_0553 | Invasive breast carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Herceptin / resveratrol combinations improved the cytotoxic profile of herceptin in both T47D and MCF-7 breast cancer cell lines. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | The chemomodulatory effects of resveratrol and didox on herceptin cytotoxicity in breast cancer cell lines. Sci Rep. 2015 Jul 9;5:12054. | |||
